[{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BNT323","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"DB-1311","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Expanded Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"DB-1305","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DB-1311","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNT325","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DB-1202","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DB-1310","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DB-1419","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1312","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":1.3,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"DB-1311","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ Duality Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DB-2304","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duality Biologics","amount2":1.2,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Duality Biologics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Agreement","leadProduct":"DB-1324","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ GSK"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DB-1317","moa":"ADAM9","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Duality Biologics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
